Synaptogenix (TAOX) Financials

Synaptogenix (NASDAQ: TAOX) showed a dramatic improvement in profitability in Q1 2026, but the results were heavily influenced by a large one-time “other income” gain rather than core operating performance.

For the quarter ended March 31, 2026, the company reported revenue of $388,774 versus $91,728 in Q4 2025 and $0 in Q1 2025. That’s a meaningful step up in top-line activity, but operating expenses still overwhelmed gross profit, with SG&A of $1.68 million and R&D of $28,600 driving an operating loss of $1.32 million.

The headline number was net income of $4.25 million, but that came mainly from $5.54 million in other income. In the prior quarter, the company posted a $7.68 million net loss, so this looks like a sharp swing, but not necessarily evidence of a sustainably profitable business model.

Cash flow tells a more cautious story. Synaptogenix generated negative operating cash flow of $1.68 million in Q1 2026 and ended the quarter with a net cash decrease of $1.85 million. The company did avoid major investing outflows in the quarter, but operations are still burning cash.

The balance sheet improved from the prior year, though liquidity remains mixed. As of March 31, 2026, Synaptogenix had $3.65 million in cash and equivalents, $31.0 million in total assets, and $4.88 million in total liabilities. That compares with $14.37 million in cash at the end of Q2 2025 and $23.26 million in total equity, so cash is down meaningfully from earlier periods, but the company still has a solid current asset base.

Over the last four years, the most important trend is that operating losses have generally persisted, even as revenue has occasionally appeared. The company has also relied on preferred equity activity and other non-operating items to support results, which makes the earnings profile more volatile and harder to predict.

• Q1 2026 revenue increased to $388,774 from $91,728 in Q4 2025, showing some improvement in business activity.
• Net income turned positive at $4.25 million, a sharp reversal from a $7.68 million loss in the prior quarter.
• Total current assets of $30.2 million provide a substantial asset base relative to current liabilities of $1.1 million.
• Total liabilities were only $4.9 million, which is modest compared with the company’s asset base.
• The quarter’s profitability was driven mainly by other income, not by operating margin improvement.
• Operating expenses remained high at $1.71 million, limiting the benefit of higher revenue.
• Cash and equivalents were $3.65 million at quarter-end, which is workable but not especially large given the cash burn.
• Operating cash flow was negative at $1.68 million, indicating the core business is still consuming cash.
• The company posted a net cash outflow of $1.85 million in the quarter.
• Historically volatile results and reliance on non-operating gains make the turnaround look less durable.

Bottom line: Synaptogenix’s Q1 2026 report looks better on the surface, but the improvement was largely driven by one-time or non-operating items. Retail investors should focus on whether the company can convert its revenue gains into sustained operating profits and positive cash flow before treating this as a true turnaround.